Literature DB >> 7214802

The use of metrizamide (amipaque) to visualise the gastrointestinal tract in children: a preliminary report.

M Cohen, W L Smith, J A Smith, E L Gresham, R Schreiner, J Lemons.   

Abstract

Metrizamide (amipaque) has not been used previously as a diagnostic contrast agent in the gastrointestinal tract. Metrizamide is a water-soluble isotonic contrast material having many advantages over barium and existing hypertonic water-soluble agents. There are many clinical situations in children in which metrizamide should be the contrast agent of choice for investigating the gastrointestinal tract. Four neonates are presented in whom barium or gastrografin were absolutely contraindicated. In each case metrizamide gave excellent visualization of the gastrointestinal tract. It could be followed through be bowel giving excellent visualisation even up to 120 h after ingestion. No harmful effects were noted in the four cases studied.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7214802     DOI: 10.1016/s0009-9260(80)80006-7

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  4 in total

1.  History of gastrointestinal imaging in pediatrics.

Authors:  E B Singleton
Journal:  Pediatr Radiol       Date:  1995

2.  The effects of metrizamide on the lung.

Authors:  B A Alford; P Dee; P Feldman
Journal:  Pediatr Radiol       Date:  1983

3.  Bedside upper gastrointestinal series in critically ill low birth weight infants.

Authors:  Gopi K Nayak; Terry L Levin; Jessica Kurian; Anirudh Kohli; Steven H Borenstein; Harold S Goldman
Journal:  Pediatr Radiol       Date:  2014-05-08

4.  The use of low-osmolar water-soluble contrast in videofluoroscopic swallowing exams.

Authors:  Julie A Harris; Detlef Bartelt; Molly Campion; Bob W Gayler; Bronwyn Jones; Andrea Hayes; Judith Haynos; Seanne Herbick; Therese Kling; Arpana Lingaraj; Michele Singer; Heather Starmer; Christine Smith; Kim Webster
Journal:  Dysphagia       Date:  2013-03-26       Impact factor: 3.438

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.